Enlivex Therapeutics (ENLV) Investor presentation summary

Business overview and strategy

• Focuses on quality longevity through medical breakthroughs and a prediction markets treasury.

• Advanced clinical-stage Allocetra immunotherapy targets age-related osteoarthritis and inflammatory diseases.

• Holds the largest institutional position in RAIN, a leading decentralized prediction market governance token.

• Treasury includes a $1B digital asset portfolio and a $2.6B in-the-money option to acquire RAIN tokens, providing significant anti-dilutive coverage.

• Management team has a strong track record in drug approvals and shareholder value creation.

Clinical program and Allocetra mechanism

• Allocetra is an off-the-shelf cell therapy designed to restore macrophage homeostasis, addressing inflammatory and autoimmune diseases.

• Uses allogeneic apoptotic cells to reprogram macrophages, promoting immune balance and resolution of inflammation.

• Simple, scalable manufacturing process enables cost-effective, ready-to-use therapy.

• Platform supports multiple indications, including osteoarthritis and sepsis.

• Extensive IP protection with patents in major markets, expected through 2043.

Osteoarthritis market and unmet need

• Knee osteoarthritis (KOA) is highly prevalent, affecting 32M Americans and projected to reach 78M by 2040.

• KOA increases all-cause mortality risk by 21% and is associated with reduced mobility, comorbidities, and social isolation.

• No approved disease-modifying treatments; current options are limited to pain relief, steroids, and surgery.

• Market size projected to grow from $6.88B in 2023 to $15.7B by 2030.

• Macrophages are an emerging therapeutic target in osteoarthritis.